186 related articles for article (PubMed ID: 25899606)
1. Ascorbic Acid Reduces the Adverse Effects of Delayed Administration of Tissue Plasminogen Activator in a Rat Stroke Model.
Allahtavakoli M; Amin F; Esmaeeli-Nadimi A; Shamsizadeh A; Kazemi-Arababadi M; Kennedy D
Basic Clin Pharmacol Toxicol; 2015 Nov; 117(5):335-9. PubMed ID: 25899606
[TBL] [Abstract][Full Text] [Related]
2. Recombinant tissue plasminogen activator induces blood-brain barrier breakdown by a matrix metalloproteinase-9-independent pathway after transient focal cerebral ischemia in mouse.
Copin JC; Bengualid DJ; Da Silva RF; Kargiotis O; Schaller K; Gasche Y
Eur J Neurosci; 2011 Oct; 34(7):1085-92. PubMed ID: 21895804
[TBL] [Abstract][Full Text] [Related]
3. Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia.
Liu W; Hendren J; Qin XJ; Liu KJ
Stroke; 2009 Jul; 40(7):2526-31. PubMed ID: 19478225
[TBL] [Abstract][Full Text] [Related]
4. Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion.
Pfefferkorn T; Rosenberg GA
Stroke; 2003 Aug; 34(8):2025-30. PubMed ID: 12855824
[TBL] [Abstract][Full Text] [Related]
5. Albumin ameliorates tissue plasminogen activator-mediated blood-brain barrier permeability and ischemic brain injury in rats.
Tang J; Li YJ; Mu J; Li Q; Yang DY; Xie P
Neurol Res; 2009 Mar; 31(2):189-94. PubMed ID: 19298760
[TBL] [Abstract][Full Text] [Related]
6. Intravenous administration of a GPIIb/IIIa receptor antagonist extends the therapeutic window of intra-arterial tenecteplase-tissue plasminogen activator in a rat stroke model.
Zhang L; Zhang ZG; Zhang C; Zhang RL; Chopp M
Stroke; 2004 Dec; 35(12):2890-5. PubMed ID: 15514182
[TBL] [Abstract][Full Text] [Related]
7. Tissue plasminogen activator extravasated through the cerebral vessels: evaluation using a rat thromboembolic stroke model.
Harada T; Kano T; Katayama Y; Matsuzaki T; Tejima E; Koshinaga M
Thromb Haemost; 2005 Oct; 94(4):791-6. PubMed ID: 16270632
[TBL] [Abstract][Full Text] [Related]
8. Detrimental effects of post-treatment with fatty acids on brain injury in ischemic rats.
Yang DY; Pan HC; Yen YJ; Wang CC; Chuang YH; Chen SY; Lin SY; Liao SL; Raung SL; Wu CW; Chou MC; Chiang AN; Chen CJ
Neurotoxicology; 2007 Nov; 28(6):1220-9. PubMed ID: 17854901
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke.
Zhang Z; Zhang L; Yepes M; Jiang Q; Li Q; Arniego P; Coleman TA; Lawrence DA; Chopp M
Circulation; 2002 Aug; 106(6):740-5. PubMed ID: 12163437
[TBL] [Abstract][Full Text] [Related]
10. Analysis of combined treatment of embolic stroke in rat with r-tPA and a GPIIb/IIIa inhibitor.
Ding G; Jiang Q; Zhang L; Zhang ZG; Li L; Knight RA; Ewing JR; Wang Y; Chopp M
J Cereb Blood Flow Metab; 2005 Jan; 25(1):87-97. PubMed ID: 15678115
[TBL] [Abstract][Full Text] [Related]
11. Ethanol plus caffeine (caffeinol) for treatment of ischemic stroke: preclinical experience.
Aronowski J; Strong R; Shirzadi A; Grotta JC
Stroke; 2003 May; 34(5):1246-51. PubMed ID: 12690223
[TBL] [Abstract][Full Text] [Related]
12. Hyperthermia masks the neuroprotective effects of tissue plaminogen activator.
Noor R; Wang CX; Shuaib A
Stroke; 2005 Mar; 36(3):665-9. PubMed ID: 15705940
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration in a rat model of embolic stroke.
Zhang L; Zhang ZG; Zhang R; Morris D; Lu M; Coller BS; Chopp M
Circulation; 2003 Jun; 107(22):2837-43. PubMed ID: 12756151
[TBL] [Abstract][Full Text] [Related]
14. Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator--treated patients.
Alvarez-Sabín J; Molina CA; Montaner J; Arenillas JF; Huertas R; Ribo M; Codina A; Quintana M
Stroke; 2003 May; 34(5):1235-41. PubMed ID: 12677014
[TBL] [Abstract][Full Text] [Related]
15. Blood-brain barrier permeability and tPA-mediated neurotoxicity.
Abu Fanne R; Nassar T; Yarovoi S; Rayan A; Lamensdorf I; Karakoveski M; Vadim P; Jammal M; Cines DB; Higazi AA
Neuropharmacology; 2010 Jun; 58(7):972-80. PubMed ID: 20060006
[TBL] [Abstract][Full Text] [Related]
16. Infarct reduction in rats following intraventricular administration of either tissue plasminogen activator (tPA) or its non-protease mutant S478A-tPA.
Yi JS; Kim YH; Koh JY
Exp Neurol; 2004 Oct; 189(2):354-60. PubMed ID: 15380485
[TBL] [Abstract][Full Text] [Related]
17. 17β-estradiol attenuates breakdown of blood-brain barrier and hemorrhagic transformation induced by tissue plasminogen activator in cerebral ischemia.
Li M; Zhang Z; Sun W; Koehler RC; Huang J
Neurobiol Dis; 2011 Dec; 44(3):277-83. PubMed ID: 21816222
[TBL] [Abstract][Full Text] [Related]
18. Extension of the thrombolytic time window with minocycline in experimental stroke.
Murata Y; Rosell A; Scannevin RH; Rhodes KJ; Wang X; Lo EH
Stroke; 2008 Dec; 39(12):3372-7. PubMed ID: 18927459
[TBL] [Abstract][Full Text] [Related]
19. Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator.
Molina CA; Ribo M; Rubiera M; Montaner J; Santamarina E; Delgado-Mederos R; Arenillas JF; Huertas R; Purroy F; Delgado P; Alvarez-Sabín J
Stroke; 2006 Feb; 37(2):425-9. PubMed ID: 16373632
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinase activation and blood-brain barrier breakdown following thrombolysis.
Kelly MA; Shuaib A; Todd KG
Exp Neurol; 2006 Jul; 200(1):38-49. PubMed ID: 16624294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
